Aeolus Pharmaceuticals Inc. (AOLS) Stock Quote

Detailed Quote for Aeolus Pharmaceuticals Inc. (AOLS)

close 52 Week Information

52 Week High

February 15, 2011

Close: 1.10

52 Week Low

January 6, 2012

Close: 0.30

Today

Last Price
0.35

Change $
0.01

Change %
2.94%

Tick
N/A

Bid
0.20

Bid Size
5,000

Ask
0.74

Ask Size
2,500

Open
0.35

High
0.35

Low
0.34

Prev Close
0.34

Last Trade
2/10/12

Volume
19.25 k

52 Wk Hi
1.10

52 Wk Low
0.30

Market Cap
21.16 m

Ex-Div Date
N/A

Div Rate
N/A

Yield
N/A

Shares
60,470,718

EPS (TTM)
N/A

PE Ratio
N/A

close Exchange Information Listed On OTC Bulletin Board Consolidated (OTCBB) Exchange
OTCBB

News and Media for Aeolus Pharmaceuticals Inc. (AOLS)

Sector News | Topic News

News for AOLS

Wed, Feb 08, 2012

2:38 PM

Aeolus' AEOL 10150 Protects Lung Tissue From Radiation by Modulating PTEN Levels, Reducing Oxidative Stress and Apoptosis - Marketwire

Tue, Feb 07, 2012

6:00 AM

Positive Data on AEOL 11207 in Pre-Clinical Epilepsy Model Published in the Journal of Neurobiology of Disease - Marketwire

Tue, Jan 17, 2012

6:58 AM

Aeolus to Present at the Noble Financial Capital Markets' 8th Annual Equity Conference - Marketwire

Tue, Dec 27, 2011

7:12 PM

Aeolus Pharmaceuticals Announces Fiscal Year 2011 Results - Marketwire

Wed, Dec 07, 2011

11:18 AM

Aeolus to Present at the 22nd Annual Oppenheimer Healthcare Conference - Marketwire

Wed, Nov 09, 2011

9:05 AM

Aeolus to Present at the Lazard Capital Markets 8th Annual Healthcare Conference - Marketwire

Tue, Nov 01, 2011

8:00 AM

Aeolus Pharmaceuticals Announces Positive Results From Study of AEOL 10150 and Neupogen(R) as Combination Therapy for Treatment of Acute Radiation Syndrome - Marketwire

Mon, Oct 24, 2011

10:02 AM

Aeolus to Present at the 10th Annual BIO Investor Forum - Marketwire

7:02 AM

Aeolus Pharmaceuticals Announces NIH Counteract Grant Award to Develop AEOL 10150 as a Treatment Against Nerve Agent Exposure - Marketwire

Mon, Oct 10, 2011

11:56 AM

Aeolus Pharmaceuticals Announces $12.7 Million NIH Counteract Grant Award to Continue Development of AEOL 10150 as a Treatment Against Chlorine and Sulfur Mustard Gas Exposure - Marketwire

Wed, Oct 05, 2011

11:28 AM

Roth Capital Initiates Equity Research Analyst Coverage on Aeolus - Marketwire

Fri, Sep 23, 2011

1:27 PM

Aeolus Pharmaceuticals Files Request for Orphan Drug Designation of AEOL 10150 for Mitigation, and/or Treatment of Delayed Effects of Acute Radiation Exposure of the Lung - Marketwire

Tue, Sep 06, 2011

5:42 PM

Aeolus to Present at Stifel Nicolaus' Annual Healthcare Conference - Marketwire

Thu, Sep 01, 2011

11:19 AM

Aeolus Pharmaceuticals' Announces Presentation of AEOL10150 Data at the 14th International Congress of Radiation Research - Marketwire

Mon, Aug 29, 2011

2:34 PM

Ladenburg Thalmann Initiates Equity Research Analyst Coverage on Aeolus - Marketwire

Thu, May 26, 2011

7:33 PM

Noble Financial Initiates Equity Research Analyst Coverage on Aeolus - Marketwire

More News for AOLS >>

Tags for Aeolus Pharmaceuticals Inc.

Research stocks or mutual funds related to Aeolus Pharmaceuticals Inc. by keywords or tags. Find companies that have a similar focus to AOLS. The keywords below have been associated to AOLS by either user submission or electronic means.

Drugs Healthcare Common Stock Pharmaceutical Preparation Manufacturing (325412) Pharmaceutical Preparations (2834)